Human epidermal growth factor receptor 2 (HER 2) is an important immunohistochemical (IHC) biomarker for breast cancer (BC) to determine the eligibility of HER 2 targeted therapies both for classical HER 2 overexpression and HER 2 low status For correct treatment decision, accurate and precise HER 2 IHC testing is fundamental. In this study, we evaluated if cell lines with relevant and critical expression levels of HER 2 in combination with artificial intelligence (AI) could be used to identify inaccurate HER 2 IHC assays.
Birgit Truumees1, Jeppe Thagaard2, Stine Amtoft Nielsen2, Mateusz Tylicki2, Lise Emanuelsen1, Søren Nielsen1
- NordiQC, Department of Pathology, Aalborg University Hospital, Denmark
- Visiopharm A/S, Denmark
Disclosures:
Birgit Truumees: None; Jeppe Thagaard: Employee, Visiopharm A/S; Stine Amtoft Nielsen: Employee, Visiopharm A/S; Mateusz Tyli ck i: Employee, Visiopharm A/S; Lise Emanuelsen: None; Søren Nielsen: None.